Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 275-283

  Coukos, George ^a   Makrigiannakis, Antonis ^a   Montas, Sacha ^a   Kaiser, Larry R ^a   Toyozumi, Takane ^a   Benjamin, Ivor ^a   Albelda, Steven M ^a   Rubin, Stephen C ^a   Molnar Kimber, Katherine L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Herpes simplex virus; Intraperitoneal therapy; Ovarian cancer; Viral oncolytic therapy

Indexed keywords

RIBONUCLEOTIDE REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE MUTATION; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MESOTHELIUM CELL; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR VOLUME; VIRUS REPLICATION;

ANIMALS; CARCINOMA; CELL TRANSFORMATION, VIRAL; DNA, RECOMBINANT; DNA, VIRAL; EPITHELIUM; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; INFUSIONS, PARENTERAL; MICE; MICE, SCID; MUTATION; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VIRULENCE; VIRUS REPLICATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 0034032455     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700130     Document Type: Article

References (45)

1. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by Grarresting rapamycin-receptor complex. Nature. 1994;369:756-775.
2. Randazzo BP, Kucharczuk JC, Litzky LA, et al. Herpes simplex 1716-an ICP 34.5 mutant-is severely replication restricted in human skin xenografts in vivo. Virology. 1996;223:392-395.
3. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995; 92:1411-1415.
4. 134.5, a gene nonessential for growth in culture. Science. 1990;250:1262-1265.
5. Poon A, Roizman B. Differentiation of the shut-off of protein synthesis by virion host shutoff and mutant ICP34.5 genes of herpes simplex virus 1. Virology. 1997;229:98-105.
6. McKie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours: Evaluation of a potentially effective clinical therapy. Br J Cancer. 1996;74:745-752.
7. Mineta T, Rabkin S, Martuza R. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
8. Mineta T, Rabkin S, Yazaki T, et al. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
9. MacLean M, Ul-Fareed M, Roberson L, Harland J, Brown S. Herpes simplex virus type 1 deletion variant 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J Gen Virol. 1991;72:631-639.
10. Andreansky S, Soroceanu L, Flotte E, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57:1502-1509.
11. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998;5:121-130.
12. Kesari S, Randazzo B, Valyi-Nagy T, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest. 1995;73:636-648.
13. Valyi-Nagy T, Farced M, O'Keefe J, et al. The herpes simplex virus type 1 strain 17+ g-34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol. 1994;75:2059-2063.
14. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther. 1997;8:2057-2068.
15. Pyles RB, Warnick RE, Chalk C, Szanti BE, Parysek L. A novel multiply mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther. 1997;8:533-544.
16. Randazzo B, Kerasi S, Gesser R, et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology. 1995;211:94-101.
17. Yazaki T, Manz H, Rabkin S, Martuza R. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995;55:4752-4756.
18. Coukos G, Rubin SC, Molnar-Kimber KL. Application of recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther Mol Biol. 1998;3:78-89.
19. Kucharczuk JC, Randazzo B, Elshami AA, et al. Use of a replication-restricted, recombinant herpes virus to treat localized human malignancy. Cancer Res. 1997;57:466-471.
20. Randazzo B, Bhat M, Kesari S, et al. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol. 1997;108:933-937.
21. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2173-2185.
22. Carroll N, Chiocca E, Takahashi K, Tanabe K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg. 1996;224:323-329.
23. Benjamin I, Rubin SC. Modern treatment options in epithelial ovarian carcinoma. Curr Opin Obstet Gynecol. 1998;10:29-32.
24. Ries L. Survival and treatment differences by age. Cancer. 1993;71:524-529.
25. Coukos G, Rubin S. Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol. 1998; 9:783-792.
26. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 1999;5:1523-1537.
27. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology. 3rd ed. St. Louis, MO: Mosby-Year Book, Inc. 1998:282-350.
28. Chou J, Poon A, Johnson J, Roizman B. Differential response of human cells to deletions and stop codons in the γ34.5 gene of herpes simplex virus. J Virol. 1994;68: 8304-8311.
29. Toda M, Martuza R, Kojima H, et al. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998;160:4457-4464.
30. Advani S, Sibley G, Song P, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998;5: 160-165.
31. Brandt C, Imesch P, Robinson N, et al. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology. 1997;229:283-291.
32. Thomas J, Kanangat S, Rouse BT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: Implications in herpetic stromal keratitis. J Interferon Cytokine Res. 1998;18:681-690.
33. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the "bystander effect": A cytokine cascade. Exp Hematol. 1996;24:829-838.
34. Ito M, Watanabe M, Kamiya H, Sakurai M. Herpes simplex virus type 1 induces apoptosis in peripheral blood T lymphocytes. J Infect Dis. 1997;175:1220-1224.
35. Wilson S, Pedroza L, Beuerman R, Hill JM. Herpes simplex virus type-1 infection of corneal epithelial cells induces apoptosis of the underlying keratocytes. Exp Eye Res. 1997;64:775-779.
36. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988;62:196-205.
37. Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem. 1983;54: 257-266.
38. Yamada Y, Kimura H, Morishima T, et al. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis. 1991;164:1091-1097.
39. Clarke L, Duerr A, Yeung K, et al. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis. 1997;176:286-288.
40. Mann GJ, Musgrove EA, Fox RM, et al. Ribonucleotide reductase Mj subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 1988;48:5151-5156.
41. Mangiarotti R, Bottone MG, Danova M, et al. Bivariate flow cytometric analysis of DNA content versus immunopositivity for ribonucleotide reductase M1 subunit in the cell cycle. Cytometry. 1998;32:78-85.
42. Kuo ML, Kinsella TJ. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 1998;58:2245-2252.
43. 1 phase restriction point block. J Clin Invest. 1991;87:519-527.
44. Hurta RA, Wright JA Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor-β1. J Cell Biochem. 1995;57:543-556.
45. Fan H, Villegas C, Huang A, et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 1998;58:1650-1653.